Ping An Biomedical Co., Ltd. (PASW)
| Market Cap | 15.67M +1.9% |
| Revenue (ttm) | 3.70M -57.6% |
| Net Income | -546,599 |
| EPS | -0.63 |
| Shares Out | 3.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,541 |
| Open | 4.77 |
| Previous Close | 4.88 |
| Day's Range | 4.55 - 5.26 |
| 52-Week Range | 3.07 - 30.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 24, 2026 |
About PASW
Ping An Biomedical Co., Ltd., through its subsidiaries, provides supply chain management services in the apparel industry in China, Hong Kong, Cambodia, and Europe. The company offers market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. It also engages in the manufacturing and trading of yarns, textiles, and finished garments; real estate property investment; and warehousing services. The company serves brand owners, textile manufacturers, apparel sourcing agents... [Read more]
Financial Performance
In fiscal year 2025, Ping An Biomedical's revenue was 34.15 million, a decrease of -61.03% compared to the previous year's 87.62 million. Losses were -12.83 million, 899.0% more than in 2024.
Financial numbers in CNY Financial StatementsNews
Ping An Biomedical Co. files $300M mixed securities shelf
17:02 EDT Ping An Biomedical Co. (PASW) files $300M mixed securities shelf
Ping An Biomedical Co Ltd trading resumes
09:36 EDT Ping An Biomedical Co Ltd trading resumes
Ping An Biomedical Co Ltd trading halted, volatility trading pause
09:31 EDT Ping An Biomedical Co Ltd trading halted, volatility trading pause
Ping An Biomedical Registration statement: Registration filing
Ping An Biomedical filed a registration statement on October 23, 2026, providing details about a securities offering with the SEC.
Ping An Biomedical Co Ltd trading halted, news pending
19:50 EDT Ping An Biomedical Co Ltd trading halted, news pending
Ping An Biomedical Co. to acquire three tumor cell-related technology patents
Ping An Biomedical Co. (PASW) announced its entry into a letter of intent with Future Biotechnology Group for the planned acquisition of three tumor cell-related medical technology patents covering ar...
Ping An Biomedical Announces Planned Acquisition of Three Tumor Cell-Related Medical Technology Patents to Build a Core Oncology and Biotech Intellectual Property Portfolio
HONG KONG, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced its entry into a letter of intent with Future Biotechnology Group Co., Limited ...
Ping An Biomedical Announces 1-for-40 Reverse Stock Split
HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (“Ping An Bio” or the “Company”) announced that its board of directors has approved a 1-for-40 reverse stock sp...
Ping An Biomedical, Yuan Sheng Mei Yan sign cooperation agreement
Ping An Biomedical signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services. Under the agreement, Yuan Sheng Mei Yan will serve as a channel development service provider…
Ping An Biomedical and Yuan Sheng Mei Yan Sign Strategic Cooperation Agreement, Targeting RMB 500 Million in Sales Over Three Years
HONG KONG, July 22, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (hereinafter referred to as “Ping An Biomedical”) announced that it has formally signed a strategic cooperation...
Ping An Biomedical Co. announces all resolutions passed at AGM
Ping An Biomedical announced that shareholders have approved all five resolutions at the company’s 2026 Annual General Meeting, providing full authorization for an overhaul of its share capital struct...
All Resolutions Passed at Ping An Biomedical AGM, Clearing Path for Restructured Share Capital
HONG KONG, March 19, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that shareholders have approved all five resolutions at th...
Ping An Biomedical Co. files to sell 13.61M ordinary shares for holders
16:53 EST Ping An Biomedical Co. (PASW) files to sell 13.61M ordinary shares for holders
Ping An Biomedical Registration statement: Registration Filing
Ping An Biomedical filed a registration statement on February 13, 2026, providing details about a securities offering with the SEC.
Ping An Biomedical Annual report: Q4 2025
Ping An Biomedical has published its Q4 2025 annual report on January 30, 2026.
Ping An Biomedical announces investment in Future Biotechnology Group
Ping An Biomedical entered into a non-binding memorandum with Future Biotechnology Group. The Investment Memorandum outlines an initial investment of $30M to be paid in cash, as well as subsequent…
Ping An Biomedical Co., Ltd Announces Strategic Investment in Future Biotechnology Group to Advance Collaborative Development of the Biopharmaceutical Industry
HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the “Inv...
Ping An Biomedical enters share purchase agreements with investors
Ping An Biomedical has entered into a series of share purchase agreements with several investors: Yao Jinbo, Chairman and CEO of 58 Group; Wang Donghui, Founder and Managing Partner of…
Ping An Biomedical Co., Ltd. Receives Strategic Investment from Leading Industry Capital, Accelerating Growth in Biopharmaceutical Innovation
HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share purchase ...
Ping An Biomedical Co. receives Nasdaq Minimum Bid Price Deficiency Letter
Ping An Biomedical Co. (PASW) announced receipt of Nasdaq Minimum Bid Price Deficiency Letter. On November 24, 2025, Ping An Biomedical Co. received a letter from the Listing Qualifications staff…
Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter
Hong Kong, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced receipt of Nasdaq Minimum Bid Price Deficiency Letter.
Majestic Ideal Holdings Ltd Announces Approval of Name Change to "Ping An Biomedical Co., Ltd." at Extraordinary General Meeting
HONG KONG, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Majestic Ideal Holdings Ltd (NASDAQ: MJID) (the “Company”) announced that during the Extraordinary General Meeting of Shareholders (the “Meeting”) held to...
Majestic Ideal Holdings Limited Announced Closing of Initial Public Offering
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Majestic Ideal Holdings Limited (Nasdaq: MJID) (the “Company”), a provider of SCM services in the apparel industry delivering one-stop solution, today annou...
Majestic Ideal Holdings Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Majestic Ideal Holdings Limited (Nasdaq: MJID) (the “Company”), a provider of SCM services in the apparel industry delivering one-stop solution, today annou...